"id:ID","label","uuid","studyDesignRationale","studyInvestigationalInterventions","documentVersion","bcCategories","description","studyEstimands","name","id"
"820","","fb197f05-5ec8-47f8-b11e-56878e5f53c4","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","[]","","[]","The main design for the study","[]","Study Design 1","StudyDesign_1"
